These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12588776)

  • 1. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
    Capell WH; DeSouza CA; Poirier P; Bell ML; Stauffer BL; Weil KM; Hernandez TL; Eckel RH
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):307-13. PubMed ID: 12588776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
    Koh KK; Han SH; Quon MJ; Yeal Ahn J; Shin EK
    Diabetes Care; 2005 Jun; 28(6):1419-24. PubMed ID: 15920062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
    Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
    Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
    Fabbrini E; Mohammed BS; Korenblat KM; Magkos F; McCrea J; Patterson BW; Klein S
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2727-35. PubMed ID: 20371660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
    Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
    Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.
    Playford DA; Watts GF; Croft KD; Burke V
    Atherosclerosis; 2003 May; 168(1):169-79. PubMed ID: 12732401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance vessel endothelial function in healthy humans during transient postprandial hypertriglyceridemia.
    Gudmundsson GS; Sinkey CA; Chenard CA; Stumbo PJ; Haynes WG
    Am J Cardiol; 2000 Feb; 85(3):381-5. PubMed ID: 11078311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
    Hamilton SJ; Chew GT; Davis TM; Watts GF
    Clin Sci (Lond); 2010 Feb; 118(10):607-15. PubMed ID: 20047560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability.
    Okumura T; Fujioka Y; Morimoto S; Tsuboi S; Masai M; Tsujino T; Ohyanagi M; Iwasaki T
    Am J Med Sci; 2002 Nov; 324(5):247-53. PubMed ID: 12449445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia.
    Marchesi S; Lupattelli G; Lombardini R; Roscini AR; Siepi D; Vaudo G; Pirro M; Sinzinger H; Schillaci G; Mannarino E
    J Clin Pharm Ther; 2003 Oct; 28(5):419-24. PubMed ID: 14632967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.
    Rosenson RS; Helenowski IB; Tangney CC
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):439-47. PubMed ID: 20922563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
    Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Oh PC; Sakuma I; Lee Y; Han SH; Shin EK
    Int J Cardiol; 2016 Oct; 221():342-6. PubMed ID: 27424313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
    Rosenson RS; Huskin AL; Wolff DA; Helenowski IB; Rademaker AW
    Atherosclerosis; 2008 Jun; 198(2):381-8. PubMed ID: 18242616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.